QuidelOrtho completes acquisition of LEX Diagnostics for about $100 million cash

Quidel Corporation

Quidel Corporation

QDEL

0.00
  • QuidelOrtho completed acquisition of LEX Diagnostics for cash consideration of about USD 100 million.
  • LEX VELO System received FDA 510(k) clearance and CLIA waiver in February 2026.
  • Platform is designed to deliver multiplex RT-PCR results for Flu A, Flu B, COVID-19 in about six to 10 minutes from a swab sample.
  • QuidelOrtho expects to start a U.S. commercial launch of LEX VELO later in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604200712PR_NEWS_USPR_____LA37688) on April 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.